Palvella Therapeutics (PVLA) Profit After Tax (2013 - 2026)
Palvella Therapeutics (PVLA) reported Profit After Tax of -$15.8 million for Q1 2026, down 92.28% year-over-year from -$204.2 million in Q1 2025, and down 24.01% on a QoQ basis from -$12.7 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of Profit After Tax data on file, last reported at -$15.8 million in Q1 2026.
- Quarterly Profit After Tax fell 92.28% year-over-year to -$15.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49.3 million (down 113.43% YoY) and the FY2025 annual result came in at -$41.7 million, down 139.27% from the prior year.
- Profit After Tax slipped to -$15.8 million in Q1 2026 per PVLA's latest filing, from -$12.7 million in the prior quarter.
- Across five years, Profit After Tax topped out at $38.6 million in Q4 2023 and bottomed at -$15.8 million in Q1 2026.
- The 5-year median for Profit After Tax is -$8.8 million (2025), against an average of -$5.1 million.
- The widest annual swing landed in 2023, when Profit After Tax soared 138.6%; it then sank 223.34% in 2025.
- Tracing PVLA's Profit After Tax over 5 years: stood at -$9.7 million in 2022, then jumped by 496.98% to $38.6 million in 2023, then tumbled by 110.22% to -$4.0 million in 2024, then tumbled by 221.79% to -$12.7 million in 2025, then slipped by 24.01% to -$15.8 million in 2026.
- Per Business Quant, the three latest PVLA Profit After Tax figures stand at -$15.8 million (Q1 2026), -$12.7 million (Q4 2025), and -$11.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | -15.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.77 Mn |
| Dec 31, 2025 | -12.71 Mn |
| Sep 30, 2025 | -11.35 Mn |
| Jun 30, 2025 | -9.47 Mn |
| Mar 31, 2025 | -8.20 Mn |
| Dec 31, 2024 | -3.95 Mn |
| Sep 30, 2024 | -6.78 Mn |
| Jun 30, 2024 | -4.17 Mn |
| Mar 31, 2024 | -2.54 Mn |
| Dec 31, 2023 | 38.65 Mn |
| Sep 30, 2023 | -10.75 Mn |
| Jun 30, 2023 | 3.98 Mn |
| Mar 31, 2023 | -13.20 Mn |
| Sep 30, 2022 | -9.74 Mn |
| Jun 30, 2022 | -10.30 Mn |
| Mar 31, 2022 | -5.10 Mn |
| Dec 31, 2021 | -9.54 Mn |
| Sep 30, 2021 | -16.54 Mn |
| Jun 30, 2021 | -15.50 Mn |
| Mar 31, 2021 | -4.20 Mn |
| Dec 31, 2020 | -14.40 Mn |
| Sep 30, 2020 | -14.28 Mn |
| Jun 30, 2020 | -4.95 Mn |
| Mar 31, 2020 | -3.60 Mn |
| Dec 31, 2019 | -771,000.00 |
| Sep 30, 2019 | -2.59 Mn |
| Jun 30, 2019 | -11.76 Mn |
| Mar 31, 2019 | -10.35 Mn |
| Dec 31, 2018 | -11.68 Mn |
| Sep 30, 2018 | -6.15 Mn |
| Jun 30, 2018 | -203,000.00 |
| Mar 31, 2018 | -8.71 Mn |
| Dec 31, 2017 | 7.49 Mn |
| Sep 30, 2017 | -7.06 Mn |
| Jun 30, 2017 | -10.09 Mn |
| Mar 31, 2017 | -7.99 Mn |
| Dec 31, 2016 | -6.56 Mn |
| Sep 30, 2016 | -6.20 Mn |
| Jun 30, 2016 | -5.88 Mn |
| Mar 31, 2016 | -4.16 Mn |
| Dec 31, 2015 | -2.90 Mn |
| Sep 30, 2015 | -3.92 Mn |
| Jun 30, 2015 | -3.53 Mn |
| Mar 31, 2015 | -3.70 Mn |
| Sep 30, 2014 | -2.02 Mn |
| Jun 30, 2014 | -2.88 Mn |
| Mar 31, 2014 | -779,905.00 |
| Dec 31, 2013 | -2,198.00 |
| Sep 30, 2013 | -5,762.00 |
| Jun 30, 2013 | -274.00 |